Sugi Predict

Sugi Predict / Compounds / SCHEMBL26119968

SCHEMBL26119968

SCHEMBL26119968

Cc1cccc(C2=N[C@H](C(=O)O)CS2)c1O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 2/20 0.50
▸ GPR35 Q9HC97 1/20 0.43
▸ HPGD P15428 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ CYP3A4 P08684 2/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ ELANE P08246 1/20 0.33
▸ CTSG P08311 1/20 0.33
▸ MYC P01106 1/20 0.33
▸ TRPA1 O75762 1/20 0.33
▸ GAA P10253 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HTR2A P28223 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26119975 1.00 HTR2B (0.50) HTR2BGPR35HPGDALDH1A1KDM4E
SCHEMBL15602812 0.86 HTR2B (0.59) HTR2BGPR35HPGDALDH1A1HSD17B10
SCHEMBL26117956 0.83 HTR2B (0.50) HTR2BGPR35
SCHEMBL26117960 0.83 HTR2B (0.50) HTR2BGPR35
SCHEMBL1268161 0.83 HTR2B (0.47) HTR2BGPR35HPGDALDH1A1KDM4E
SCHEMBL1268158 0.83 HTR2B (0.47) HTR2BGPR35HPGDALDH1A1KDM4E
SCHEMBL26119108 0.81 HTR2B (0.43) HTR2BHPGDALDH1A1KDM4EHSD17B10
SCHEMBL26119102 0.81 HTR2B (0.43) HTR2BHPGDALDH1A1KDM4EHSD17B10
SCHEMBL1268172 0.81 HTR2B (0.47) HTR2BGPR35KDM4EKMT2AMEN1
SCHEMBL1268173 0.81 HTR2B (0.47) HTR2BGPR35KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197388-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE EMPRESS THERAPEUTICS, INC. 2025-06-19 — — US disclosed
CN-119487012-A Compounds, pharmaceutical compositions and methods for treating inflammatory bowel disease 旗舰创业创新六公司 2025-02-18 — — CN disclosed
EP-4499618-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE Flagship Pioneering Innovations VI, LLC (US) 2025-02-05 — — EP disclosed
WO-2023192388-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2023-10-05 — — WO disclosed
WO-2023192388-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197388-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE SI, VIP, APC HTR2B 2431/4885GPR35 1704/4885HPGD 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.